Chinese Journal of Antituberculosis ›› 2020, Vol. 42 ›› Issue (2): 108-114.doi: 10.3969/j.issn.1000-6621.2020.02.006
• Original Articles • Previous Articles Next Articles
QIU Lei,ZHANG Shao-yan,GUO Xiao-yan,FU Ji-you,TIAN Li-ming,ZHANG Hui-yong,LU Zhen-hui()
Received:
2019-12-16
Online:
2020-02-10
Published:
2020-02-19
Contact:
Zhen-hui LU
E-mail:Dr_luzh@shutcm.edu.cn
QIU Lei,ZHANG Shao-yan,GUO Xiao-yan,FU Ji-you,TIAN Li-ming,ZHANG Hui-yong,LU Zhen-hui. Clinical value of chemotherapy regimen and Qinbudan tablet on the retreatment of retreated smear-positive pulmonary tuberculosis[J]. Chinese Journal of Antituberculosis, 2020, 42(2): 108-114. doi: 10.3969/j.issn.1000-6621.2020.02.006
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2020.02.006
基线资料 | 对照组(88例) | 观察组(93例) | 统计检验值 | P值 |
---|---|---|---|---|
患者来源[例数,构成比(%)] | χ2=0.651 | 0.420 | ||
门诊 | 29(33.0) | 36(38.7) | ||
住院 | 59(67.0) | 57(61.3) | ||
性别[例数,构成比(%)] | χ2=0.001 | 0.971 | ||
男 | 57(64.8) | 60(64.5) | ||
女 | 31(35.2) | 33(35.5) | ||
并发症[例数,构成比(%)] | χ2=0.866 | 0.352 | ||
有 | 68(77.3) | 77(82.8) | ||
无 | 20(22.7) | 16(17.2) | ||
年龄[岁,M(Q1,Q3)] | 36.00(25.00,51.50) | 37.00(22.50,52.00) | U=3946.500 | 0.679 |
身高(cm, | 166.96±6.56 | 167.83±8.80 | t=0.751 | 0.453 |
体质量(kg, | 56.05±10.06 | 55.77±10.08 | t=0.187 | 0.851 |
病程[月,M(Q1,Q3)] | 16.00(6.25,58.75) | 16.00(6.00,46.00) | U=3900.000 | 0.585 |
症状 | 对照组(88例) [例数(构成比,%)] | 观察组(93例) [例数(构成比,%)] | χ2值 | P值 |
---|---|---|---|---|
潮热 | 6.415 | 0.013 | ||
有效 | 60(68.2) | 78(83.9) | ||
无效 | 28(31.8) | 15(16.1) | ||
颧红 | 5.943 | 0.015 | ||
有效 | 47(53.4) | 66(71.0) | ||
无效 | 41(46.6) | 27(29.0) | ||
盗汗 | 4.195 | 0.041 | ||
有效 | 65(73.9) | 80(86.0) | ||
无效 | 23(26.1) | 13(14.0) | ||
咳痰 | 5.516 | 0.019 | ||
有效 | 62(70.5) | 79(84.9) | ||
无效 | 26(29.5) | 14(15.1) | ||
口渴 | 14.144 | <0.001 | ||
有效 | 48(54.5) | 75(80.6) | ||
无效 | 40(45.5) | 18(19.4) | ||
咽干 | 11.391 | 0.001 | ||
有效 | 58(65.9) | 81(87.1) | ||
无效 | 30(34.1) | 12(12.9) | ||
咳嗽 | 2.011 | 0.156 | ||
有效 | 62(70.5) | 75(80.6) | ||
无效 | 26(29.5) | 18(19.4) | ||
胸痛 | 0.273 | 0.601 | ||
有效 | 42(47.7) | 48(51.6) | ||
无效 | 46(52.3) | 45(48.4) |
评分项目 分组 | 首诊得分 [0d;M(Q1,Q3)] | 治疗结束时得分 [24d;M(Q1,Q3)] | 平均秩次 (mean rank) | U值 | P值 | |||||
---|---|---|---|---|---|---|---|---|---|---|
健康变化 | 3387.000 | 0.027 | ||||||||
对照组 | 25.00(25.00,50.00) | 75.00(75.00,100.00) | 82.99 | |||||||
观察组 | 25.00(25.00,50.00) | 75.00(75.00,100.00) | 98.58 | |||||||
生理机能 | 3345.000 | 0.028 | ||||||||
对照组 | 80.00(65.00,95.00) | 90.00(85.00,95.00) | 82.51 | |||||||
观察组 | 80.00(65.00,90.00) | 95.00(90.00,95.00) | 99.03 | |||||||
生理职能 | 4087.000 | 0.988 | ||||||||
对照组 | 75.00(6.25,100.00) | 100.00(25.00,100.00) | 90.94 | |||||||
观察组 | 100.00(25.00,100.00) | 75.00(50.00,100.00) | 91.05 | |||||||
情感职能 | 4034.000 | 0.848 | ||||||||
对照组 | 33.30(0,100.00) | 100.00(66.67,100.00) | 90.34 | |||||||
观察组 | 66.67(0,100.00) | 100.00(66.67,100.00) | 91.62 | |||||||
社会功能 | 3519.500 | 0.095 | ||||||||
对照组 | 75.00(50.00,100.00) | 112.50(100.00,125.00) | 97.51 | |||||||
观察组 | 75.00(43.75,87.50) | 112.50(87.50,112.50) | 84.84 | |||||||
躯体疼痛 | 3694.000 | 0.178 | ||||||||
对照组 | 40.00(40.00,50.00) | 100.00(80.00,100.00) | 86.48 | |||||||
观察组 | 40.00(40.00,50.00) | 100.00(84.00,100.00) | 95.28 | |||||||
精力 | 3009.000 | 0.002 | ||||||||
对照组 | 67.50(50.00,80.00) | 75.00(65.00,85.00) | 78.69 | |||||||
观察组 | 60.00(47.50,75.00) | 85.00(75.00,85.00) | 102.27 | |||||||
精神健康 | 3819.500 | 0.436 | ||||||||
对照组 | 64.00(52.00,72.00) | 76.00(64.00,84.00) | 87.69 | |||||||
观察组 | 68.00(56.00,76.00) | 80.00(68.00,84.00) | 93.93 | |||||||
一般健康状况 | 3211.000 | 0.012 | ||||||||
对照组 | 35.00(27.75,52.00) | 66.00(48.25,80.00) | 82.99 | |||||||
观察组 | 32.00(25.00,50.00) | 72.00(66.00,82.00) | 100.47 |
[1] | Zhao Y, Xu S, Wang L , et al. National survey of drug-resis-tant tuberculosis in China. N Engl J Med, 2012,366(23):2161-2170. |
[2] | 孙建, 梁宗安 . 复治肺结核患者临床特点分析. 西部医学, 2014,26(7):831-832. |
[3] | 邓树利, 陈志宇, 区子昌 . 158例老年复治肺结核临床特点及治疗效果分析. 中国实用医药, 2012,7(11):73-74. |
[4] | 王玉红, 王智慧, 李晓倩 , 等. 初治、复治肺结核患者细胞免疫功能与营养状况比较. 中国热带医学, 2019,19(2):132-135. |
[5] | 商勇, 陆燕春, 解承鑫 , 等. 不同肺结核类型患者细胞免疫功能相关性研究. 临床肺科杂志, 2017,22(7):1176-1179. |
[6] | 陆城华, 鹿振辉, 张惠勇 . 复方芩部丹方对气阴亏虚型耐多药肺结核患者生存质量的影响. 中医学报, 2015,30(11):1566-1568. |
[7] | 蒋洪 . 复方芩部丹方治疗气阴亏虚型耐多药肺结核疗效观察. 现代中西医结合杂志, 2016,25(22):2468-2470. |
[8] | 薛鸿浩, 张惠勇, 秦朝辉 , 等. 复方芩部丹颗粒治疗阴虚火旺型耐多药肺结核. 吉林中医药, 2015,35(3):258-261. |
[9] | 中华人民共和国国家卫生和计划生育委员会. WS 196—2017 结核病分类.2017-11-09. |
[10] | 中华人民共和国国家食品药品监督管理总局. 证候类中药新药临床研究技术指导原则.2018-11-06. |
[11] | 杨亦德, 谢红东, 金茜 , 等. SF-36量表评估含左氧氟沙星化疗方案治疗复治涂阳肺结核的意义. 中国现代医生, 2016,54(10):15-19. |
[12] | 张学忠, 李霞, 蒋晓艳 . 复治涂阳肺结核治疗中左氧氟沙星联合抗结核化疗方案的应用价值分析. 中国社区医师, 2017,33(11):40-41. |
[13] | 甘维利, 谭先玉 . 左氧氟沙星替代治疗复治肺结核的结果分析. 中国卫生产业, 2013, 10(31):114,116. |
[14] | 刘桂华, 李史来 . 莫西沙星及利福布汀方案治疗复治涂阳肺结核的效果. 中国当代医药, 2015,22(24):51-53. |
[15] | 杜新卫 . 卷曲霉素及左氧氟沙星治疗方案对复治涂阳肺结核的临床价值. 中国现代药物应用, 2015,9(15):135-136. |
[16] | 王俊杰 . 观察卷曲霉素联合左氧氟沙星治疗复治涂阳肺结核患者的临床效果. 中国现代药物应用, 2016,10(19):175-176. |
[17] | 邓长国, 岳冀, 李曦 , 等. 首次复治涂阳肺结核治疗方案研究. 四川医学, 2014,35(9):1108-1113. |
[18] | 问亚锋 . 利福布汀超短程治疗初次复治涂阳肺结核32例临床研究. 中国药业, 2015,24(23):63-65. |
[19] | 姬淑英, 张林 . 利福布汀与左氧氟沙星联合治疗老年初治涂阳肺结核的疗效. 中外医疗, 2015,34(29):144-146. |
[20] | 林清, 顾文芬 . 百生肼和利福喷汀治疗复治涂阳肺结核的疗效分析. 临床合理用药杂志, 2014,7(5):33-34. |
[21] | 孙晓婷 . 微卡辅助治疗复治涂阳肺结核的疗效观察. 临床医药实践, 2013,22(5):352-353. |
[22] | 董秀坤 . 卡介菌多糖核酸对初治涂阳肺结核的临床价值. 中国继续医学教育, 2015,32(7):120-121. |
[23] | 陈应松 . 使用阿米卡星和左氧氟沙星对复治涂阳肺结核患者进行治疗的效果分析. 当代医药论丛, 2016,14(10):76-77. |
[24] | Bauer M, Leavens A, Schwartzman K . A systematic review and meta-analysis of the impact of tuberculosis on health-related quality of life. Qual Life Res, 2013,22(8):2213-2235. |
[25] | Brown J, Capocci S, Smith C , et al. Health status and quality of life in tuberculosis. Int J Infect Dis, 2015,32:68-75. |
[26] | Guo N, Marra F, Marra CA . Measuring health-related quality of life in tuberculosis: a systematic review. Health Qual Life Outcomes, 2009,7:14. |
[27] | 张伯礼, 吴勉华 . 中医内科学. 北京:中国中医药出版社, 2017: 108-114. |
[28] | 薛鸿浩, 张惠勇, 鹿振辉 , 等. 邵长荣运用芩部丹治疗肺结核的经验. 山东中医药大学学报, 2010,34(6):520-522. |
[29] | 蒋洪 . 复方芩部丹方治疗气阴亏虚型耐多药肺结核疗效观察. 现代中西医结合杂志, 2016,25(22):2468-2470. |
[30] | 薛鸿浩, 张惠勇, 鹿振辉 . 芩部丹体外抑制结核分枝杆菌的实验研究. 中医药导报, 2017,23(2):55-56. |
[31] | 王莉新, 吴燕燕, 王易 . “芩部丹”中三种单体对结核分枝杆菌作用下TLR2表达的影响. 中国药理学报, 2011,27(9):1284-1287. |
[1] | Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Inspire-CODA Research Group. Expert consensus on the treatment of tuberculosis with contezolid [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 123-129. |
[2] | Li Xuelian, Zhang Hongyan, Wang Jun, Wang Qingfeng, Ma Liping, Chu Naihui, Nie Wenjuan. Safety of extended delamanid use in drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 164-168. |
[3] | Shi Lulu, Jing Hui, Liang Min, Li Xuezheng. Analysis of clinical results of blood concentration detection of antituberculosis drugs by liquid chromatography-tandem mass spectrometry [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 886-891. |
[4] | Duan Shujuan, Wang Wei, Pang Yu, Li Ling. Research progress on the regulation of host anti-tuberculosis effect by tyrosine kinase inhibitors [J]. Chinese Journal of Antituberculosis, 2024, 46(5): 584-589. |
[5] | Jiayinati Jingesi, Wang Xinqi, Liu Nianqiang, Wang Senlu, Yipaer Aihaiti, Feng Jianyu, Huang Tao, Kedieryekezi Wufuer. Analysis of treatment completeness and its influencing factors of preventive treatment among 387 latent tuberculosis infection cases [J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1496-1503. |
[6] | Shi Chunjing, Liu Xing, Li Longfen, Li Wenming, Zhang Huajie, Wang Ge, Zeng Haiyan, Liu Li, Shen Lingjun. Research progress on the effects of bedaquiline,delamanid and pretomanid on liver function in the treatment of multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1560-1565. |
[7] | Sha Wei. Significance and challenges of the implementation of PAN-TB treatment strategy for tuberculosis prevention and control [J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1188-1192. |
[8] | Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Beijing Chest Hospital, Capital Medical University. Expert consensus on clinical monitoring and management of QTc interval prolongation caused by anti-tuberculous drugs [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 8-17. |
[9] | Wang Honghong, Guo Shaochen, Zhou Wenqiang, Liu Zhongquan, Zhu Hui, Lu Yu. Influence of linezolid blood concentration on hematological toxicity in drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2023, 45(2): 165-171. |
[10] | Ge Qiping, Zhang Lijie, Huang Xuerui, Jiang Guanglu, Han Xiqin, Wang Jingping, Du Jian, Ma Yan, Gao Weiwei. Effect of a new treatment regimen on patients with initially retreated drug-sensitive pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(11): 1078-1083. |
[11] | Chen Fang, Zhang Xiaofo, Zhou Haiyi, Zhang Feng, Wang Manzhi. Analysis of status and influencing factors associated with anti-tuberculosis drug-related liver injury in children [J]. Chinese Journal of Antituberculosis, 2023, 45(1): 45-51. |
[12] | LIU Hai-ting, LI Dong-shuo, ZHANG Lei, WANG Ning, WANG Bin, DING Yang-ming, YAO Rong, LU Yu. A preliminary study on the synergy and mechanism of pyrifazimine and bedaquiline [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 646-653. |
[13] | LU Ni-hong, SHEN Ling-jun, LIU Hong-lu, CHEN Yang-jun, YANG Yan, DU Ying-rong. Clinical value of ESAT-6, immune and inflammatory indexes in the diagnosis of anti-tuberculosis drug-induced liver injury [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 654-659. |
[14] | NIE Wen-juan, ZHOU Wen-qiang, CHU Nai-hui. Research progress on pharmacokinetics and drug interaction of bedaquiline [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 716-719. |
[15] | XUE Yu, ZHANG Jing, NIE Wen-juan. The efficacy and safety of regimen containing bedaquiline in the treatment of elderly drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2022, 44(6): 582-586. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||